Drugmaker Hikma’s generic version of Amarin Pharma’s cardiovascular medication Vascepa did not infringe Amarin’s patents, the U.S. Supreme Court ruled.
The post Supreme Court backs generic drugmaker in ‘skinny label’ patent case appeared first on Maryland Daily Record.
